ATE355304T1 - Radiomarkierte vip-analoge zur diagnose und therapie - Google Patents

Radiomarkierte vip-analoge zur diagnose und therapie

Info

Publication number: ATE355304T1
Authority: AT; Austria
Prior art keywords: vip; radiolabeled; receptor; agent; imaging
Prior art date: 2000-02-18

Application number

AT00950907T

Other languages

English (en)

Inventor

Anand C Burman

Sudhanand Prasad

Rama Mukherjee

Sarjana Dutt

Rajan Sharma

Rinku Ahuja

Anil Mishra

Lazar T Matthew

Original Assignee

Dabur Res Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-18

Filing date

2000-07-31

Publication date

2006-03-15

2000-07-31 Application filed by Dabur Res Foundation filed Critical Dabur Res Foundation

2006-03-15 Application granted granted Critical

2006-03-15 Publication of ATE355304T1 publication Critical patent/ATE355304T1/de

Links

238000003745 diagnosis Methods 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 abstract 4
206010028980 Neoplasm Diseases 0.000 abstract 3
102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 abstract 3
108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 abstract 2
102400000015 Vasoactive intestinal peptide Human genes 0.000 abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 2
239000012216 imaging agent Substances 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
238000000163 radioactive labelling Methods 0.000 abstract 2
230000003439 radiotherapeutic effect Effects 0.000 abstract 2
206010027476 Metastases Diseases 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000003384 imaging method Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1
230000008685 targeting Effects 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
238000012800 visualization Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Optics & Photonics (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Radar Systems Or Details Thereof (AREA)
Transceivers (AREA)
Electrotherapy Devices (AREA)

AT00950907T 2000-02-18 2000-07-31 Radiomarkierte vip-analoge zur diagnose und therapie ATE355304T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IN137DE2000		2000-02-18

Publications (1)

Publication Number	Publication Date
ATE355304T1 true ATE355304T1 (de)	2006-03-15

Family

ID=11097029

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00950907T ATE355304T1 (de)	2000-02-18	2000-07-31	Radiomarkierte vip-analoge zur diagnose und therapie

Country Status (7)

Country	Link
US (1)	US6608174B1 (de)
EP (1)	EP1257575B1 (de)
AT (1)	ATE355304T1 (de)
AU (1)	AU2000263935A1 (de)
CA (1)	CA2405714A1 (de)
DE (1)	DE60033697D1 (de)
WO (1)	WO2001060863A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9029505B2 (en)	2009-08-14	2015-05-12	Phasebio Pharmaceuticals, Inc.	Modified vasoactive intestinal peptides
US9782454B2 (en)	2010-04-22	2017-10-10	Longevity Biotech, Inc.	Highly active polypeptides and methods of making and using the same
CA2873553C (en)	2011-06-06	2020-01-28	Phasebio Pharmaceuticals, Inc.	Use of modified vasoactive intestinal peptides in the treatment of hypertension
KR20150143440A (ko) *	2013-02-15	2015-12-23	토마스 제퍼슨 유니버시티	떨어져 나가거나 순환 중인 종양세포를 생물학적 유액 내에서 탐지하는 방법
WO2014145718A2 (en)	2013-03-15	2014-09-18	Longevity Biotech, Inc.	Peptides comprising non-natural amino acids and methods of making and using the same
CN114652817B (zh)	2015-02-09	2026-04-17	费斯生物制药公司	用于治疗肌肉疾病和病症的方法和组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4605641A (en)	1984-10-09	1986-08-12	Hoffmann-La Roche Inc.	Synthetic vasoactive intestinal peptide analogs
US4734400A (en)	1984-10-09	1988-03-29	Hoffmann-La Roche Inc.	Synthetic vasoactive intestinal peptide analogs
GB8525852D0 (en)	1985-10-19	1985-11-20	Beecham Group Plc	Compounds
US4835252A (en)	1987-02-26	1989-05-30	The Salk Institute Biotechnology/Industrial Associates, Inc.	Vasoactive intestinal peptide analogs
US5141924A (en)	1989-06-30	1992-08-25	Hoffmann-La Roche, Inc.	Synthetic vasoactive intestinal peptide analogs
DK0436005T3 (da)	1989-07-20	1995-07-03	Sandoz Ltd	Mærkede polypeptidderivater
DE69101187T2 (de)	1990-06-26	1994-09-29	Sanwa Kagaku Kenkyusho Co	VIP-Analogen und ihre Verwendung.
US5217953A (en)	1990-11-30	1993-06-08	The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services	Vasoactive intestinal peptide antagonist
US5849261A (en) *	1991-02-08	1998-12-15	Diatide, Inc.	Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
JPH05238950A (ja)	1991-04-22	1993-09-17	Sanwa Kagaku Kenkyusho Co Ltd	易吸収性ｖｉｐ製剤
AU656230B2 (en)	1991-10-11	1995-01-27	F. Hoffmann-La Roche Ag	Cyclic vasoactive peptides
US5565424A (en)	1994-02-07	1996-10-15	Ramot - University Authority For Applied Research And Industrial Development Ltd.	Superactive VIP antagonists
EP0796867B1 (de) *	1995-06-09	2003-11-05	Itoham Foods Inc.	Peptide, bronchodilator und den blutstrom verbesserndes mittel
PL345583A1 (en)	1998-07-20	2001-12-17	Sod Conseils Rech Applic	Peptide analogues of pacap

2000
- 2000-07-31 WO PCT/US2000/020874 patent/WO2001060863A1/en not_active Ceased
- 2000-07-31 US US09/629,632 patent/US6608174B1/en not_active Expired - Fee Related
- 2000-07-31 AT AT00950907T patent/ATE355304T1/de not_active IP Right Cessation
- 2000-07-31 DE DE60033697T patent/DE60033697D1/de not_active Expired - Lifetime
- 2000-07-31 AU AU2000263935A patent/AU2000263935A1/en not_active Abandoned
- 2000-07-31 CA CA002405714A patent/CA2405714A1/en not_active Abandoned
- 2000-07-31 EP EP00950907A patent/EP1257575B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE60033697D1 (de)	2007-04-12
US6608174B1 (en)	2003-08-19
EP1257575B1 (de)	2007-02-28
CA2405714A1 (en)	2001-08-23
AU2000263935A1 (en)	2001-08-27
EP1257575A1 (de)	2002-11-20
WO2001060863A1 (en)	2001-08-23

Similar Documents

Publication	Publication Date	Title
Gali et al.	2001	Synthesis, characterization, and labeling with 99mTc/188Re of peptide conjugates containing a dithia-bisphosphine chelating agent
Banerjee et al.	2014	64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer
ES2960729T3 (es)	2024-03-06	177 Lu-dota-hynic-ipsma como un radiofármaco terapéutico dirigido al antígeno prostático específico de membrana
Xu et al.	2017	99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen
EP3486249B1 (de)	2021-11-10	99mtc-edda/hynic-ipsma als radiopharmazeutikum für den nachweis der überexpression des prostata-spezifischen membranantigens
Marsouvanidis et al.	2013	Gastrin releasing peptide receptor-directed radioligands based on a bombesin antagonist: synthesis, 111In-labeling, and preclinical profile
Hernández-Jiménez et al.	2018	177Lu-DOTA-HYNIC-Lys (Nal)-Urea-Glu: Synthesis and assessment of the ability to target the prostate specific membrane antigen
Guo et al.	2009	Gallium-67-labeled lactam bridge-cyclized α-melanocyte stimulating hormone peptide for primary and metastatic melanoma imaging
ATE355304T1 (de)	2006-03-15	Radiomarkierte vip-analoge zur diagnose und therapie
Liu et al.	2019	Radionuclide-labeled peptides for imaging and treatment of CXCR4-overexpressing malignant tumors
Abouzayed et al.	2023	177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
Ferro-Flores et al.	2020	Radiolabeled protein-inhibitor peptides with rapid clinical translation towards imaging and therapy
M Rey	2010	Radiometal complexes in molecular imaging and therapy
KR20070106731A (ko)	2007-11-05	방사성표지된 갈륨 복합체, 그의 합성방법 및 악성종양에서 ｅｇｆｒ 발현의 ｐｅｔ 영상화를 위한 그의 용도
Luo et al.	2012	An 125I-labeled octavalent peptide fluorescent nanoprobe for tumor-homing imaging in vivo
JP3717402B2 (ja)	2005-11-16	映像化する方法および組成物
MY129008A (en)	2007-03-30	Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotheraphy
KR20040055784A (ko)	2004-06-26	종양의 영상 및 치료용 피에이씨에이피 조성물 및 방법
Liu et al.	2017	Metastatic melanoma imaging using a novel Tc-99m-labeled lactam-cyclized alpha-MSH peptide
JP2002516882A5 (de)	2006-07-20
Ha et al.	2012	Synthesis and evaluation of a radioiodinated bladder cancer specific peptide
CN101597323A (zh)	2009-12-09	一种用于肿瘤显像的放射性同位素标记多肽
Giblin et al.	2006	In vitro and in vivo evaluation of 111In-labeled E. coli heat-stable enterotoxin analogs for specific targeting of human breast cancers
Liolios et al.	2024	Bispecific PSMA-617/RM2 Heterodimer for Theranostics Applications in Prostate Cancer
Schweinsberg	2008	Novel 99mTc-labeled bombesin analogues with improved pharmacokinetics for targeting of gastrin-releasing-peptide receptor-positive tumors

Legal Events

Date	Code	Title	Description
2007-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties